|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:acquisition_year
|
gptkb:2019
|
|
gptkbp:ceo
|
Christine Carr
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:employees
|
over 23,000
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
gptkb:Harry_Stratford
|
|
gptkbp:headquarters
|
gptkb:Lexington,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shire Pharmaceuticals
|
|
gptkbp:market_cap
|
$62 billion (2018)
|
|
gptkbp:operates_in
|
over 100 countries
|
|
gptkbp:partnerships
|
various biotech companies
|
|
gptkbp:philanthropy
|
Shire Foundation
|
|
gptkbp:products
|
gptkb:Elaprase
gptkb:Strattera
gptkb:Adderall
gptkb:Cerezyme
gptkb:Fabrazyme
gptkb:Intuniv
gptkb:Lialda
gptkb:Replagal
gptkb:Vyvanse
Gaucher disease treatment
Hunter syndrome treatment
Attention deficit hyperactivity disorder treatment
|
|
gptkbp:research_focus
|
genetic disorders
hematology
neuroscience
gastroenterology
|
|
gptkbp:revenue
|
$15 billion (2018)
|
|
gptkbp:specializes_in
|
rare diseases
|
|
gptkbp:subsidiaries
|
gptkb:Shire_Pharmaceuticals_Ireland_Limited
gptkb:Shire_Development_LLC
gptkb:Shire_International_Gmb_H
Shire US Holdings
Shire Pharmaceuticals Limited
|
|
gptkbp:sustainability_initiatives
|
gptkb:healthcare_access
community engagement
patient advocacy
environmental responsibility
|
|
gptkbp:website
|
www.shire.com
|
|
gptkbp:bfsParent
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:bfsLayer
|
5
|